Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
OPTEL Group is a private Canadian technology company that provides end-to-end traceability, serialization, aggregation, vision inspection, and supply-chain visibility solutions for highly regulated industries, with particularly strong positioning in pharmaceuticals and medical devices. Its products help manufacturers comply with regulations such as DSCSA and EU FMD, protect against counterfeiting, improve packaging-line performance, and extend traceability beyond the factory into broader supply-chain and sustainability workflows. The company markets software platforms including Optchain for multi-tier supply-chain intelligence and VerifyBrand for serialization, traceability, and brand protection, alongside TrackSafe hardware and inspection systems for pharmaceutical production. OPTEL also has growing automation capabilities in pharma manufacturing following its 2025 acquisition of Vanguard Robotics. Although it is not a drug developer, it is clearly healthcare-related because its core business supports pharmaceutical and medical-device manufacturing, compliance, and product integrity worldwide.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on OPTEL Group.